Investor Presentaiton

Repotrectinib: Potential Best-in-Class ROS1 Inhibitor in NSCLC Highly Potent & Differentiated Small Molecule Repotrectinib ROS1+ TKI-Naïve NSCLC; ORR (95% CI) TKI-Pretreated Activity 79% (67.6, 87.7) ✓ ORRS of 28-42% (n=100) Market Potential Kinase CNS Activity (ROS1+ NSCLC) ROS1+ TKI-Naïve NSCLC Durability Solvent front mutation Gatekeeper mutation Ill Bristol Myers Squibb™ DOR ≥12-month DOR: 83.1% (73.1, 93.2) mDOR: 34.1 (25.6-NE) PFS • ≥12-month PFS: 76.6% (66.2, 87.0) •⚫ mPFS: 35.71 (27.40, NE) Generally Well Tolerated Safety Profile Source: Cho BC, et al. IASLC WCLC 2023 Clinically differentiated profile in NSCLC U.S. PDUFA November 27, 2023 ROS1 Prevalence: ~ 1.5% of NSCLC patients² Existing ROS1 market: ~$500-$600M³ Opportunity to roughly double the ROS1 market & achieve best- in-class share based on: Longer duration of response Higher response rate • Better safety profile tolerability Not for Product Promotional Use 151

View entire presentation